var data={"title":"Clomiphene: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clomiphene: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5925?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clomiphene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clomiphene: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153216\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Serophene [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153217\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Clomid;</li>\n      <li>Serophene</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153232\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Ovulation Stimulator;</li>\n      <li>\n        Selective Estrogen Receptor Modulator (SERM)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153219\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ovulation induction:</b> Oral: Females: <b>Note:</b> Intercourse should be timed to coincide with the expected time of ovulation (usually 5 to 10 days after a clomiphene course).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Initial course:</i> 50 mg once daily for 5 days. Begin on or about the fifth day of cycle if progestin-induced bleeding is scheduled or spontaneous uterine bleeding occurs prior to therapy. Therapy may be initiated at any time in patients with no recent uterine bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose adjustment:</i> Subsequent doses may be increased to 100 mg once daily for 5 days only if ovulation does not occur at the initial dose. Lower doses (12.5 to 25 mg daily) may be used in women sensitive to clomiphene or who consistently develop large ovarian cysts (ASRM 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Repeat courses:</i> If needed, the 5-day cycle may be repeated as early as 30 days after the previous one. Exclude the presence of pregnancy. The lowest effective dose should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maximum dose:</i> 100 mg once daily for 5 days for up to 6 cycles. Discontinue if ovulation does not occur after 3 courses of treatment; or if 3 ovulatory responses occur but pregnancy is not achieved. Long-term therapy (&gt;6 cycles) is not recommended. Re-evaluate if menses does not occur following ovulatory response. Doses have ranged from 50 to 250 mg daily, although doses &gt;100 mg daily have not been shown to increase pregnancy rates (ASRM 2013). The maximum recommended dose in women with PCOS is 150 mg daily (ESHRE/ASRM 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795865\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795866\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in patients with a history of liver disease or dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153200\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as citrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serophene: 50 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49728679\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage Forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Tablet, Oral, as citrate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Clomid: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5183724\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">The total daily dose should be taken at one time to maximize effectiveness (Dickey, 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104446\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153202\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment of ovulatory dysfunction: </b>Treatment of ovulatory dysfunction in women desiring pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ClomiPHENE may be confused with clomiPRAMINE, clonidine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clomid may be confused with clonidine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serophene may be confused with Sarafem</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153193\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Ovary enlargement (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (&le;6%), abdominal distress (&le;6%), bloating (&le;6%), nausea (&le;2%), vomiting (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breast disease (discomfort: 2%), abnormal uterine bleeding (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing/case reports: Accommodation disturbance, acne vulgaris, alopecia, anxiety, arthralgia, back pain, cardiac arrhythmia, cataract, cerebrovascular accident, chest pain, constipation, depression, dermatitis, diarrhea, dizziness, dry hair, dyspnea, ectopic pregnancy, edema, endometriosis, endometrium disease (reduced thickness), erythema, erythema multiforme, erythema nodosum, eye pain, fatigue, fever, hepatitis, hypersensitivity reaction, hypertension, hypertrichosis, hypertriglyceridemia, increased appetite, increased serum transaminases, increased urine output, insomnia, irritability, leukocytosis, macular edema, migraine, mood changes, myalgia, neoplasm, nervousness, optic neuritis, ovarian cyst, ovarian hemorrhage, ovarian hyperstimulation syndrome, palpitations, pancreatitis, paresthesia, phlebitis, photopsia, pruritus, psychosis, pulmonary embolism, retinal hemorrhage, retinal thrombosis, retinal vascular spasm, seizure, severe abdominal pain, skin rash, syncope, tachycardia, thrombophlebitis, thyroid disease, tinnitus, urinary frequency, urticaria, uterine hemorrhage, vaginal dryness, vertigo, vision loss (temporary/prolonged), vitreous detachment (posterior), weakness, weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153205\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clomiphene citrate or any of its components; liver disease or history of liver disease; abnormal uterine bleeding; enlargement or development of ovarian cyst (not due to polycystic ovarian syndrome); uncontrolled thyroid or adrenal dysfunction; presence of an organic intracranial lesion such as pituitary tumor; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hormone-dependent tumors (Clomid); thrombophlebitis, uterine fibroids, mental depression (Serophene)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Women with, or a family history of, hyperlipidemia may be at increased risk of hypertriglyceridemia. High doses of clomiphene or long durations of therapy may increase risk this risk. Pancreatitis has been reported. Pretreatment screening of triglycerides is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within a few days or weeks after therapy discontinuation. If ovaries are abnormally enlarged, withhold therapy until ovaries return to pretreatment size; reduce clomiphene dose and duration of future cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbances: Blurring or other visual symptoms can occur; symptoms may increase with higher doses or duration of therapy and in some cases may be irreversible. These visual disturbances may render some activities to be more hazardous than normal (eg, operating machinery or driving). Patients with visual disturbances should discontinue therapy and receive prompt ophthalmic evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian cancer: Prolonged use may increase the risk of borderline or invasive ovarian cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polycystic ovarian syndrome (PCOS): Use with caution in patients unusually sensitive to pituitary gonadotropins (eg, PCOS); a lower dose may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Uterine fibroids: Use caution in patients with uterine fibroids, may cause further enlargement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To minimize risks, use only at the lowest effective dose for the shortest duration of therapy (especially for the first course of therapy). Women with PCOS, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post oral contraceptive amenorrhea, and some cases of secondary amenorrhea of undetermined cause may most likely benefit from clomiphene therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: Use should be supervised by physicians who are thoroughly familiar with infertility problems and their management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple births: May result from the use of this medication; advise patient of the potential risk of multiple births before starting the treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299066\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219406\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9281&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5183299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in females who are already pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The incidence of adverse fetal effects following maternal use of clomiphene for ovulation induction is similar to those seen in the general population.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5183301\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if clomiphene is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer recommends that caution be used if administered to breastfeeding women. Clomiphene may decrease lactation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5183726\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to therapy: serum estrogen. Rule out primary pituitary or ovarian failure, endometriosis/endometrial carcinoma, adrenal disorders, thyroid disorders, hyperprolactinemia, and male infertility. Serum triglycerides.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelvic exam prior to each course of therapy; pregnancy test prior to repeat courses; ovulation (may include serum estradiol, progesterone, urinary luteinizing hormone; ultrasound) (ASRM 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clomiphene is a racemic mixture consisting of zuclomiphene (~38%) and enclomiphene (~62%), each with distinct pharmacologic properties. Clomiphene acts at the level of the hypothalamus, occupying cell surface and intracellular estrogen receptors (ERs) for longer durations than estrogen. This interferes with receptor recycling, effectively depleting hypothalamic ERs and inhibiting normal estrogenic negative feedback. Impairment of the feedback signal results in increased pulsatile GnRH secretion from the hypothalamus and subsequent pituitary gonadotropin (FSH, LH) release, causing growth of the ovarian follicle, followed by follicular rupture (ASRM 2013; Dickey 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153204\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Ovulation: 5 to 10 days following course of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Effects are cumulative; ovulation may occur in the cycle following the last treatment (Dickey 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; undergoes enterohepatic recirculation (Goldstein 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~5 days (Goldstein 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: ~6 hours (Goldstein 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily feces (42%); urine (8%); some excretion may occur for up to 6 weeks after therapy is discontinued</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153207\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ClomiPHENE Citrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (10): $68.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153208\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anexin (PY);</li>\n      <li>Biogen (PE);</li>\n      <li>Blesifen (ID);</li>\n      <li>Clofert (IN);</li>\n      <li>Clomene (PH);</li>\n      <li>Clomhexal (AU);</li>\n      <li>Clomid (AE, AR, AU, BE, BH, CH, CY, EG, FR, GB, IE, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, OM, PH, PK, QA, SA, SG, SY, TW, YE);</li>\n      <li>Clomifen (FI);</li>\n      <li>Clomihexal (ZA);</li>\n      <li>Clomipen (KR);</li>\n      <li>Clomitab (LK);</li>\n      <li>Clomoval (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Clonin (TW);</li>\n      <li>Clostil (PH);</li>\n      <li>Clostilbegyt (AE, BB, BG, BH, BM, BS, BZ, CY, EG, GY, HN, IQ, IR, JM, JO, KW, LB, LV, LY, OM, PL, PR, QA, RU, SA, SR, SY, TT, VN, YE);</li>\n      <li>Cloval (BD);</li>\n      <li>Clovertil (ID);</li>\n      <li>Dufine (PT);</li>\n      <li>Duinum (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, PH, SC, SD, SG, SL, SN, TH, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Dyneric (DE);</li>\n      <li>Fermil (AU);</li>\n      <li>Fertab (AE, KW);</li>\n      <li>Fertab-50 (PH);</li>\n      <li>Fertec (CO);</li>\n      <li>Ferticlo (PH);</li>\n      <li>Fertil (BD);</li>\n      <li>Fertilan (HK);</li>\n      <li>Fertilin (TR);</li>\n      <li>Fertiline (JO, QA);</li>\n      <li>Fertilphen (ID);</li>\n      <li>Fertimax (PH);</li>\n      <li>Fertin (ID);</li>\n      <li>Fertomid (IN);</li>\n      <li>Fervula (ID);</li>\n      <li>Fulfyl (LK);</li>\n      <li>Genex (BD);</li>\n      <li>Genoclam (ID);</li>\n      <li>Genozym (PY);</li>\n      <li>I-Clom (PH);</li>\n      <li>Ikaclomin (IL);</li>\n      <li>Ofertil (ID);</li>\n      <li>Omifin (CO, ES, MX);</li>\n      <li>Ova-Mit (BB, BM, BS, BZ, GY, JM, PR, SR, TR, TT);</li>\n      <li>Ovafin (LK);</li>\n      <li>Ovamit (EC, JO, KW, MY, TH);</li>\n      <li>Ovinum (TH);</li>\n      <li>Ovipreg (IN);</li>\n      <li>Ovulet (LK, PH);</li>\n      <li>Pergotime (BE, DK, FR, NO, SE);</li>\n      <li>Pinfetil (ID);</li>\n      <li>Profertil (ID);</li>\n      <li>Provula (ID);</li>\n      <li>Reomen (BD);</li>\n      <li>Serofene (AR, MX, VE);</li>\n      <li>Serophene (AE, AT, AU, BH, CH, CY, CZ, EG, HK, IQ, IR, JO, KR, KW, LB, LY, NL, NZ, OM, PH, QA, SA, SG, SY, TH, TW, UY, VN, YE);</li>\n      <li>Serpafar (GR);</li>\n      <li>Zimaquin (CL, EC, PE, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clomid (clomiphene) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clomid (clomiphene) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clomiphene [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickey RP and Holtkamp DE, &ldquo;Development, Pharmacology, and Clinical Experience With Clomiphene Citrate,&rdquo; <i>Hum Reprod Update</i>, 1996; 2(6):483-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/9111183/pubmed\" target=\"_blank\" id=\"9111183\">9111183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/22531097/pubmed\" target=\"_blank\" id=\"22531097\">22531097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein SR, Siddhanti S, Ciaccia AV, et al. &ldquo;A Pharmacological Review of Selective Oestrogen Receptor Modulators,&rdquo; <i>Hum Reprod Update</i>, 2000, 6(3):212-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/10874566/pubmed\" target=\"_blank\" id=\"10874566\">10874566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Society of Obstetricians and Gynaecologists of Canada -Canadian Fertility and Andrology Society (SOGC-CFAS) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/22416285/pubmed\" target=\"_blank\" id=\"22416285\">22416285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine (ASRM). Use of clomiphene citrate in infertile women: a committee opinion. <i>Fertil Steril</i>. 2013;100(2):341-348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/23809505/pubmed\" target=\"_blank\" id=\"23809505\">23809505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Purvin VA, &ldquo;Visual Disturbance Secondary to Clomiphene Citrate,&rdquo; <i>Arch Ophthalmol</i>, 1995, 113(4):482-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/7710399/pubmed\" target=\"_blank\" id=\"7710399\">7710399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serophene (clomiphene) [product monograph]. Mississauga, Ontario, Canada: EMD Serono, A Division of EMD Inc., Canada: December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokol RZ, &ldquo;Prevention and Management of Complications Occurring During Treatment With Clomiphene,&rdquo; <i>Drug Saf</i>, 1990, 5(5):313-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/2222865/pubmed\" target=\"_blank\" id=\"2222865\">2222865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, &ldquo;Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,&rdquo; <i>Fertil Steril</i>, 2008, 89(3):505-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/18243179/pubmed\" target=\"_blank\" id=\"18243179\">18243179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vause TDR, Cheung AP, Sierra S, et al, &quot;Ovulation Induction in Polycystic Ovary Syndrome,&quot; <i>J Obstet Gynaecol Can</i>, 2010, 32(5):495-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clomiphene-drug-information/abstract-text/20500959/pubmed\" target=\"_blank\" id=\"20500959\">20500959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker AB, Eldridge PR, and MacFarlane IA, &ldquo;Clomiphene-Induced Pituitary Apoplexy in a Patient With Acromegaly,&rdquo; <i>J Endocrinol</i>, 1995, 144:29.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9281 Version 112.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F153216\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F153217\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F153232\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F153219\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15795865\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795866\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F153200\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F153186\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49728679\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5183724\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104446\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F153202\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F153238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153193\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153205\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299066\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219406\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5183299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5183301\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5183726\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F153204\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F153207\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F153208\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9281|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clomiphene-patient-drug-information\" class=\"drug drug_patient\">Clomiphene: Patient drug information</a></li></ul></div></div>","javascript":null}